Skip to content
Resources > Reports

AlphaCut: Forecasting IPO and Deal Momentum Beyond 2025

By Barbara Tague, Financial Research Leader
IndustryFinancial Services, IPO

Recent findings from the AlphaSense platform indicate that H1 2025 marked the strongest H1 since 2021 for the U.S. IPO market.

In this report, we surface trending insights and perspectives within analyst research reports, key expert transcripts, and industry publications.

AlphaCut is your trusted source for the trends and intelligence making the most waves in today’s market. Download the report today to streamline and simplify your deal workflow.

About the Author

  • Barbara Tague, Financial Research Leader

    Barb is a Financial Research Leader covering the financial services segment at AlphaSense. Previously, she spent more than a decade at institutional investment managers and at a SaaS startup leading business development, content, and product initiatives.

Explore more

All articles

APAC Macro Briefing 2026: Risk Meets Opportunity

In this report, we show how resources and workflows available in the AlphaSense platform can help contextualize the APAC macro environment, exploring the key implications for corporate leaders and investors across sectors.
Report
Title slide for "APAC Macro Briefing 2026: Risk Meets Opportunity" with a map of the Asia-Pacific region.

Top AI Use Cases for Private Equity

In this report, discover how private equity teams are leveraging AI to accelerate conviction with speed. With purpose built, AI-driven solutions like AlphaSense, teams are gaining a competitive advantage with custom workflows and unmatched content sets for the most differentiated deal intelligence.
Report
Top AI Use Cases For Private Equity by Barb Tague, Financial Research Leader. Illustration featuring isometric buildings and currency symbols.

AI in Drug Development 2026: From Experimentation to Execution

Learn how AI is reshaping drug development in real time, turning AI execution into a key competitive differentiator.
Report
Presentation slide titled "AI in Drug Development 2026: From Experimentation to Execution" by Sara Mallatt and Sean Carmichael, with line art of laboratory equipment.

Transform intelligence
into advantage

Develop bold strategies, seize opportunities,
and lead with clarity and confidence.